MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells

Table 1 Relationship between expression levels of miR-133b and clinicopathologic parameters in 140 GC cases

Clinicopathologic parameters	miR-133b expression			p-value
Clinicopathologic parameters	Low (n = 46)	Middle (n = 47)	High (n =47)	p-value
Age (years)
≤60	20	16	28	*0.04
>60	26	31	19
Gender
Male	39	30	31	0.05
Female	7	17	16
Differentiation
High, middle	14	17	9	0.18
Low	32	30	38
Location
Distal third	28	23	24	0.63
Middle third	13	14	16
Proximal third	5	10	7
Local invasion
T1	5	6	1	0.16
T2	14	5	12
T3	10	14	13
T4	17	22	21
Lymph node metastasis
N0	7	12	13	*0.03
N1	7	7	11
N2	14	19	19
N3	18	9	4
TNM stage
I, II	22	20	22	0.86
III, IV	24	27	25

A total of 140 cases were stratified into three groups based on relative miR-133b expression (tumor/non-tumor ratio) using tertiles: miR-133b low expression (tumor/non-tumor ratio < 0.24, n = 46), miR-133b moderate expression (tumor/non-tumor ratio 0.24–0.87, n = 47) and miR-133b high expression (tumor/non-tumor ratio > 0.87, n = 47). The relationship between the miR-133b expression levels and clinicopathologic parameters was analyzed using the Pearson Chi-square test. *, p <0.05.

ISSN: 1471-2407